US Edition

Tempus AI agreed to buy cancer-monitoring firm Personalis for $1.5 billion on July 20, 2026, but instead of celebrating, investors sent both stocks tumbling. Personalis fell nearly 15% on a disappointing 6% premium, while Tempus dropped over 9% on dilution and integration risk. Wall Street remains split, with price targets ranging from Jefferies' $35 to BTIG's $80.